Biotechnology

Bristol Myers Squibb (NYSE: BMY) announced that the FDA will now decide on the biologics license application (BLA) for the subcutaneous formulation of Opdivo (nivolumab) on Dec 29, 2024. The subcutaneous formulation of Opdivo is co-formulated with Halozyme's proprietary recombinant human...

Roche (OTC: RHHBY) obtained a Breakthrough Therapy Designation for its investigational oral therapy inavolisib for treating adult breast cancer patients in the United States. The FDA granted this designation to inavolisib in combination with Ibrance (palbociclib) and Faslodex (fulvestrant) to treat...

Merck (NYSE: MRK) announced that it is discontinuing a cohort of the phase III study evaluating a co-formulation of its blockbuster PD-L1 inhibitor, Keytruda plus vibostolimab, its investigational anti-TIGIT antibody, as adjuvant treatment for patients with resected high-risk melanoma. Data from a...

Luna Innovations Inc (NASDAQ: LUNA) disclosed a strategic investment of $50 million from White Hat Capital Partners. The company will partially use the proceeds to fund the acquisition of Silixa, which was announced today, for $21.5 million in upfront cash consideration and up to an...

Robotic surgeries are going mainstream for a good reason: they make it easier for doctors to perform complex surgeries. Monogram Orthopedics Inc. (NASDAQ: MGRM), which aims to revolutionize orthopedic joint replacement surgery with its robotic technology, just got one step closer to achieving that...

Moleculin Biotech Inc (NASDAQ: MBRX) provided a preliminary update on recent clinical activity from annamycin lead development programs. Annamycin is the company's next-generation anthracycline that has been designed to be non-cardiotoxic (unlike currently prescribed anthracyclines)...

Thursday, Neurocrine Biosciences Inc (NASDAQ: NBIX) released Phase 2 study results from two signal-seeking pipeline programs in focal onset seizures and anhedonia. The investigational selective NaV 1.6 inhibitor, NBI-921352, licensed from Xenon Pharmaceuticals Inc (...

Neurocrine Biosciences Inc (NASDAQ: NBIX) released topline data from the Phase 3 CAHtalyst Pediatric Study of crinecerfont in children and adolescents with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency.  CAH is an inherited condition that affects...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) entered into a merger agreement under which its subsidiary, Pelican Technology Holdings Inc, has become a wholly owned subsidiary of Primrose Bio Inc.  Primrose Bio is a stand-alone private company focused on synthetic biology....

Needham cut the price target for Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) from $60 to $53. Needham analyst Gil Blum maintained a Buy rating. Rocket Pharmaceuticals shares rose 24.3% to $19.00 in pre-market trading. Goldman Sachs slashed Ultrapar Participações S.A. (NYSE: UGP)...

Neurocrine Biosciences Inc (NASDAQ: NBIX) announced positive topline data from the Phase 3 CAHtalyst Adult Study evaluating crinecerfont in adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD). CAH is a group of genetic conditions limiting...

The FDA approved Neurocrine Biosciences Inc's (NASDAQ: NBIX) Ingrezza (valbenazine) capsules for the treatment of adults with chorea associated with Huntington's disease (HD). Ingrezza is the only selective vesicular monoamine transporter 2 (VMAT2) inhibitor that offers an...

The Dow Jones closed lower by over 400 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision....

Novan Inc (NASDAQ: NOVN) shares are trading lower after Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that it has offered to acquire the company's assets. The deal value includes $15 million in cash and provides up to $15 million in DIP financing to Novan,...